Table 2

Drug resistance profile of HeLa.EpoA9 and HeLa.EpoB1.8 cells.

IC50s were determined after 72 h of incubation with the indicated drugs. The IC50 of HeLa.EpoA9 and HeLa.EpoB1.8 cells were divided by the IC50 of HeLa cells to indicate the fold decrease or increase in drug sensitivity.

CompoundHeLa
HeLa.EpoA9HeLa.EpoB1.8
IC50 (nm)IC50 (nm)FoldIC50 (nm)Fold
Epo A4.02 ± 0.019.95 ± 0.192.56.18 ± 0.041.5
EpoB1.96 ± 0.483.40 ± 0.081.74.41 ± 0.162.3
Taxol1.68 ± 0.0110.70 ± 0.846.44.75 ± 0.032.8
Taxotere1.42 ± 0.057.84 ± 0.155.54.89 ± 0.063.4
Discoa7.54 ± 0.1916.01 ± 0.462.16.70 ± 0.920.9
VBL0.95 ± 0.080.81 ± 0.050.91.55 ± 0.071.6
CLC10.80 ± 0.786.24 ± 0.100.64.52 ± 0.180.4
  • a Disco, discodermolide; VBL, vinblastine; CLC, colchicine.